How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Clinical Trial Supply Management Market
- By Phase of Clinical Trial: Phase I, Phase II, Phase III, Phase IV
- By Service Type: Inventory Management, Packaging and Labeling, Distribution and Logistics, Temperature Monitoring, Returns Management
- By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutes
- By Product Type: Drugs, Biologics, Medical Devices, Combination Products
- By Packaging Type: Blister Packaging, Bottle Packaging, Vial Packaging, Prefilled Syringes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Phase I leads By Phase of Clinical Trial at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Clinical Trial Supply Management Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Phase of Clinical Trial 4
Service Type 5
End User 4
Product Type 4
Packaging Type 4
Companies profiled
Catalent Inc.
Thermo Fisher Scientific Inc.
Parexel International Corporation
IQVIA Holdings Inc.
Charles River Laboratories International Inc.
Almac Group
PCI Pharma Services
Kuehne + Nagel International AG
Baxter International Inc.
Vetter Pharma International GmbH
Recipharm AB
Sharp Packaging Services
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Catalent Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Parexel International Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →IQVIA Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Almac Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PCI Pharma Services
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Kuehne + Nagel International AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Baxter International Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vetter Pharma International GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Recipharm AB
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sharp Packaging Services
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Fisher Clinical Services
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Rentschler Biopharma SE
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,703M by 2033 · 8.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Phase I40.6
- Phase II16.7
- Phase III19.1
- Phase IV23.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,020M → $2,051M · 9.1%
Europe$710.8M → $1,236M · 7.2%
Asia Pacific$649.0M → $1,236M · 8.4%
Latin America$401.8M → $776.3M · 8.6%
Middle East and Africa$309.1M → $507.2M · 6.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.902026
7.912027
7.942028
7.942029
7.972030
7.972031
7.982032
8.002033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Catalent Inc.14.3
- Thermo Fisher Scientific Inc.17.8
- Parexel International Corporation10.4
- IQVIA Holdings Inc.11.1
- Charles River Laboratories International Inc.13.4
- Almac Group5.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Phase of Clinical Trial18.1%
Service Type21.0%
End User24.9%
Product Type18.2%
Packaging Type17.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.3
- Europe21.3
- Asia Pacific21.3
- Latin America13.4
- Middle East and Africa8.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Catalent Inc. | 84 | 97 | 74 | 85 | 82 | 96 | 86 |
| Thermo Fisher Scientific Inc. | 76 | 84 | 71 | 77 | 92 | 69 | 78 |
| Parexel International Corporation | 74 | 76 | 63 | 68 | 72 | 71 | 71 |
| IQVIA Holdings Inc. | 59 | 67 | 72 | 58 | 67 | 64 | 65 |
| Charles River Laboratories International Inc. | 59 | 69 | 55 | 60 | 72 | 73 | 65 |
| Almac Group | 53 | 59 | 61 | 48 | 50 | 62 | 56 |
| PCI Pharma Services | 54 | 66 | 64 | 60 | 66 | 45 | 59 |
| Kuehne + Nagel International AG | 46 | 49 | 36 | 59 | 41 | 48 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Catalent Inc.
- Thermo Fisher Scientific Inc.
- Parexel International Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Catalent Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Thermo Fisher Scientific Inc. | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| Parexel International Corporation | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| IQVIA Holdings Inc. | ◐ | − | ◐ | ◐ | − | ◐ |
| Charles River Laboratories International Inc. | ◐ | − | − | ◐ | ◐ | ◐ |
| Almac Group | ◐ | ◐ | ◐ | − | ◐ | ✓ |
| PCI Pharma Services | − | ◐ | ◐ | ◐ | ◐ | − |
| Kuehne + Nagel International AG | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Catalent Inc.86
2Thermo Fisher Scientific Inc.78
3Parexel International Corporation71
4IQVIA Holdings Inc.65
5Charles River Laboratories International Inc.65
6PCI Pharma Services59
7Almac Group56
8Kuehne + Nagel International AG47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Catalent Inc.Thermo Fisher Scientific Inc.
Challenger1
Strong scale, closing on the leaders.
Parexel International Corporation
Contender3
Focused players with pockets of strength.
IQVIA Holdings Inc.Charles River Laboratories International Inc.PCI Pharma Services
Niche2
Specialists in a single segment or region.
Almac GroupKuehne + Nagel International AG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Phase of Clinical Trial in North America, then scale across Clinical Trial Supply Management Market — a $659M beachhead inside a $10.8B market.
Beachhead (SOM)$659Mobtainable near-term
Serviceable (SAM)$4.01Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Phase I
Best fit — highest urgency & budget in Phase of Clinical Trial.
Economic buyer79 fit
Phase II
Strong fit — clear ROI and a fast path to value.
End user67 fit
Phase III
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Phase of Clinical Trial in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Service Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve17%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Phase of Clinical Trial leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Clinical Trial Supply Management Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified21%
Evaluation14%
Closed-won7%
$12.2KCAC
$42KLTV
3.4:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Clinical Trial Supply Management Market is a durable-growth opportunity — $1.87B by 2033, compounding at 8.0%.
TAM · 2025$1.01Btoday
TAM · 2033$1.87Bforecast
CAGR8.0%2027–2033
Cumulative$12.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.87BTotal addressable market
SAM$768MServiceable available market
SOM$157MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.0% CAGR
Demand compounds through 2033, outpacing GDP across Phase of Clinical Trial.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Phase of Clinical Trial moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.87BLarge & growingTAM by 2033 at 8.0% CAGR
$768MServiceable nowreachable with today’s model
$157MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.46BBear5.2% CAGR
$1.87BBase8.0% CAGR
$2.40BBull10.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Service Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Clinical Trial Supply Management Market — a $7.65B market by 2033. Plan: grow share from 6.8% to 11.5%.
Market size · 2033$7.65Btotal addressable
Market CAGR6.4%2027–2033
Target share11.5%from 6.8% today
Revenue ambition$880Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 11.5% | At risk |
| Revenue | $479M | $880M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 37.5% | 42.3% | On track |
| Customer retention | 88.4% | 95.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Phase of Clinical Trial
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Service Type capability
A defensible second engine — invest in Service Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Phase of Clinical Trial share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Service Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $116M capacity & capability investment
- Greenlight bolt-on M&A in Service Type
- Authorise North America expansion plan
- Fund R&D program for Phase of Clinical Trial leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Clinical Trial Supply Management Market conversation — a $8.10B market you can size, segment and defend in minutes.
Market size · 2033$8.10Btotal opportunity
Growth5.1%CAGR to 2033
Addressable buyers1,101+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Phase of Clinical Trial
Goal Grow share in Phase of Clinical Trial
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 4 mopayback period
$42K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Catalent Inc.Thermo Fisher Scientific Inc.Parexel International CorporationIQVIA Holdings Inc.Charles River Laboratories International Inc.Almac GroupPCI Pharma ServicesKuehne + Nagel International AG+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Clinical Trial Supply Management Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Clinical Trial Supply Management Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Clinical Quality Management System (CQMS) Market
Market size, share, segmentation and regional forecast.
$656M market · 2025 base year
View report9-valent HPV Vaccine (9vHPV) Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportClinic Management Software Market
Market size, share, segmentation and regional forecast.
$475M market · 2025 base year
View reportCell Staining Simulation Tool Market
Market size, share, segmentation and regional forecast.
$929M market · 2025 base year
View report98% Stearyl Glycyrrhetinate Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportCognitive Informatics Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View report980nm Single Frequency Laser Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View report980nm Laser Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View report96 Well Plates Microplate Washer Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View report96 Well Plate Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View report96-Well Microplate Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportCleanroom Technologies Market
Cleanroom Technologies Market is valued at USD 9.2 Billion in 2025 and is expected to reach USD…
$9.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.